Gosset Ownership
Private
Stage
Preclinical
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Modalities
Pending AI General Information
Pending AI has developed an advanced artificial intelligence and quantum mechanics-enabled drug discovery platform that accelerates the design of novel small molecules. The company focuses on de novo drug design, structure-based drug design, high-throughput chemistry, and synthesis planning. There are no clinical results as the company provides enabling technology rather than developing its own therapeutic pipeline.
Contact Information
Website
Primary Industry
Drug Discovery Services
Corporate Office
Cambridge, Massachusetts
United States
United States
Drug Pipeline
No pipeline data available
Key Partnerships
Pending AI Funding
No funding data available
To view Pending AI's complete valuation and funding history, request access »